Amgen reported flat revenues and slightly increased earnings, meeting financial expectations. Management expressed confidence in their pipeline, especially with the progress of Denosumab, and provided guidance for modest growth in 2009. However, ongoing challenges like declining sales of Aranesp and macroeconomic uncertainties may balance out the positives, likely resulting in a neutral short-term impact on the stock price.

[0]